- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
LGC Capital signed an option with a Quebec-based company to acquire 49 percent interest, and a five percent royalty, for a cannabis processing facility set to be built in Quebec.
LGC Capital (TSXV:LG) signed an option with a Quebec-based company to acquire 49 percent interest, and a five percent royalty, for a cannabis processing facility set to be built in Quebec.
As quoted in the press release:
Subject to permitting, the AAA Trichomes processing facility will be one of the first enclosed multi-level medical cannabis producers in Quebec. Trichomes is scheduled to start operations in 2019 with an initial annual production rate of over 2,500 kilograms reaching a planned production rate of over 20,000 kilograms by 2021.
Under the terms of the exclusive option agreement, LGC plans to fund the building of the facility by way of a $4 million fully secured convertible debenture bearing interest at the rate of 10% per annum. Upon the facility being approved for cannabis cultivation and production, the debenture will automatically be converted to a 49% holding in the issued common share capital of Trichomes as well as a 5% royalty on all net sales of cannabis products.
Click here to read the full press release.
Source: www.newswire.ca
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.Â